Cytokinetics to Announce Second Quarter Results on August 8, 2024
25 juil. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at...
[Latest] US Biotechnology Market Size/Share Worth USD 1797.8 Billion by 2033 at a 12.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25 juil. 2024 13h30 HE
|
Custom Market Insights
Austin, TX, USA, July 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Biotechnology Market Size, Trends and Insights By Technology...
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
25 juil. 2024 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
25 juil. 2024 06h30 HE
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
TransCode Therapeutics, Inc. Announces Closing of Public Offering
24 juil. 2024 16h05 HE
|
TransCode Therapeutics, Inc.
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors
24 juil. 2024 11h15 HE
|
NeOnc Technologies Holdings, Inc.
NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
23 juil. 2024 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second...
Global Forensic Technologies and Services Market Insights, 2024-2030 - Rise in Gun Violence Driving Demand for Forensic Ballistics
23 juil. 2024 12h46 HE
|
Research and Markets
Dublin, July 23, 2024 (GLOBE NEWSWIRE) -- The "Forensic Technologies and Services - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
22 juil. 2024 22h30 HE
|
TransCode Therapeutics, Inc.
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22 juil. 2024 16h07 HE
|
TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t